Advances in antibody nanoconjugates for diagnosis and therapy: A review of recent studies and trends

• Published in: International journal of biological macromolecules Vol. 185; pp. 664 - 678
• Main Authors: Kadkhoda, Jamileh, Akrami-Hasan-Kohal, Mohammad, Tohidkia, Mohammad Reza, Khaledi, Samira, Davaran, Soodabeh, Aghanejad, Ayuob
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 31.08.2021
• Subjects: Antibody nanoconjugates; antigens; blood circulation; Cancer; cancer therapy; Diagnosis; drugs; Molecular imaging; mortality; nanomedicine; neoplasms; precision medicine; Therapy; toxicity; Molecular imaging; Therapy; Diagnosis; Antibody nanoconjugates; Cancer
• ISSN: 0141-8130; 1879-0003; 1879-0003
• DOI: 10.1016/j.ijbiomac.2021.06.191

Nowadays, the targeted imaging probe and drug delivery systems are the novel breakthrough area in the nanomedicine and treatment of various diseases. Conjugation of monoclonal antibodies and their fragments on nanoparticles (NPs) have a remarkable impact on personalized medicine, such that it provides specific internalization and accumulation in the tumor microenvironment. Targeted imaging and early detection of cancer is presumably the strong participant to a diminution in mortality and recurrence of cancer disease that will be the next generation of the imaging device in clinical application. These intelligent delivery systems can deliver therapeutic agents that target cancerous tissue with minimal side effects and a wide therapeutic window. Overall, the linkage between the antibody and NPs is a critical subject and requires precise design and development. The attachment of antibody nanoconjugates (Ab-NCs) on the antigen surface shouldn't affect the function of the antibody-antigen binding. Also, the stability of the antibody nanoconjugates in blood circulation is concerned to avoid the release of drug in non-targeted regions and the possible for specific toxicity while disposal to the desired site. Here, we update the recent progress of Ab-NCs to improve early detection and cancer therapy. [Display omitted] •Antibodies conjugated NPs are appealing medical platforms because of their ability to improve therapeutic results in the targeted site, reducing side effects and efficient cellular uptake.•The growth of new therapeutic and diagnostic modalities with enhanced cell specificity and sensitivity could pave the way for more effective and reliable therapy.•Nanomedicine-based targeted therapies must be paid entirely more attention to promoting cancer diagnosis and treatment.